Leap Investments’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Leap Investments’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$73K	Buy	+15,800	New	+$70K	0.05%	368
2019 Q4	–	Sell	-17,919	Closed	-$75K	–	644
2019 Q3	$75K	Buy	+17,919	New	+$143K	0.04%	381

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Leap Investments's PHAS Position: Q2 2020 in Review

Leap Investments opened a new position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2020: 15,800 shares worth $73K. The stake represents 0.05% of the portfolio and ranks #368 among its holdings. This is a return to the name: Leap Investments previously reported a position in PHAS as recently as Q3 2019.

Leap Investments first reported a position in PHAS in Q3 2019 and has held it in 2 quarters since. The position peaked at $75K in Q3 2019. 60 funds tracked by Wall St. Rank hold PHAS as of Q2 2020.

Leap Investments held 15,800 shares of PhaseBio Pharmaceuticals, Inc. Common Stock worth $73K as of Q2 2020.
PhaseBio Pharmaceuticals, Inc. Common Stock was a new Leap Investments position in Q2 2020.
PhaseBio Pharmaceuticals, Inc. Common Stock made up 0.05% of Leap Investments's portfolio in Q2 2020, its #368 holding.
Leap Investments first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q3 2019 and has held it in 2 quarters since.
Leap Investments's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $75K in Q3 2019.
60 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.